OPTIMISMM is the only phase III trial to show a significant PFS benefit in R/R MM patients with prior exposure to lenalidomide.
A once-weekly regimen of carfilzomib plus dexamethasone improved response and delayed progression better than a twice-weekly regimen in R/R MM.
Despite paying nearly double per month for first-line treatment in the US, patients with mCRC have survival outcomes similar to their Canadian counterparts.
The presence of MSI-high was predictive of Lynch syndrome, which was found to be associated with a much wider spectrum of cancers than previously thought.
A pooled analysis including data from over 8,000 men showed survival outcomes were better for black men, after adjusting for prognostic variables.
In the Abi Race study, response to abiraterone was greater and longer lasting in black men with prostate cancer, compared with white men.
Women with HER2-positive early breast cancer achieved similar disease-free survival with 6 months of adjuvant trastuzumab compared with a 12-month duration, according to the phase III PERSEPHONE trial.
While HCT is an important benefit for FL patients, the optimal approach remains up for debate.
A retrospective study shows 30 patients need to be treated with adjuvant therapy to prevent 1 death at 3 years.
Researchers from MD Anderson say their study results "open the field of immunoprevention in LS to checkpoint inhibitors as an immune interception strategy."